Skip to main
STOK

STOK Stock Forecast & Price Target

STOK Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 22%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Stoke Therapeutics is a biotechnology company with a promising pipeline and a unique approach to treating genetic diseases through up-regulation of protein expression. Their lead candidate, zorevunersen, has shown potential for disease modification in patients with Dravet syndrome and has been granted FDA Breakthrough Therapy designation. The company's TANGO technology has the potential to address hundreds of disease states caused by haploinsufficiencies. While there are risks involved in drug discovery and development, Stoke has a strong potential for success in the market, with a peak annual sales estimate of $1 billion for zorevunersen.

Bears say

Stoke Therapeutics is a biotechnology company that utilizes RNA medicine to restore protein levels and treat genetic disorders. However, the company has experienced large operating losses and net losses in recent quarters, and it may struggle to obtain FDA approval for its lead asset, zorevunersen, due to concerns over the drug's ability to effectively treat Dravet syndrome. Additionally, Stoke faces potential risks related to stock price volatility, financial stability, and intellectual property rights. Considering these factors, the company's stock may not be a profitable investment at this time.

STOK has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 22% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Stoke Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Stoke Therapeutics Inc (STOK) Forecast

Analysts have given STOK a Strong Buy based on their latest research and market trends.

According to 9 analysts, STOK has a Strong Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Stoke Therapeutics Inc (STOK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.